Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing
September 5, 2014
- Januvia Retains Its No. 1 Spot in the GP Market in July: Anterio’s “Mind Share” Ranking
September 5, 2014
- Takeda Transfers All Shares of Its Subsidiary Nippon-Rinshosha to Medical Tribune
September 5, 2014
- Sanofi Launches Prostate Cancer Agent Jevtana
September 5, 2014
- Kaketsuken Completes New Manufacturing Plant for Increasing Production Capacity of Hepatitis B Vaccine
September 5, 2014
- US Court Backs Jury Verdict in Actos Suit, Orders Takeda to Pay US$6 Billion in Punitive Damages
September 5, 2014
- TMRC to Collaborate with Children’s Hospital Los Angeles to Develop Treatment for Chemotherapy-Induced Neutropenia
September 4, 2014
- Bristol-Myers’ Dual Oral Hepatitis C Regimen Debuts in Japan
September 4, 2014
- Prostate Cancer Drug Zytiga Now Available in Japan: Janssen
September 4, 2014
- GSK’s 2013 Payments to Health Professionals in Japan at 10 Billion Yen
September 4, 2014
- Torii’s Sublingual Hay Fever Drug to Hit Market in October
September 4, 2014
- Ichiro Yoshimoto to Become New President of CMIC
September 4, 2014
- CMIC Holdings to Boost Domestic CSO Business, Converting Its Subsidiary to JV with UDG Healthcare
September 4, 2014
- Drug Price Settlement Rate Might Hit 70% in September: Wholesaler Exec
September 3, 2014
- Daiichi Sankyo Espha to Launch AG Versions of Cravit after NHI Price Listing in December
September 3, 2014
- Ono Launches Opdivo, Making Full-Fledged Entry to Oncology Field
September 3, 2014
- Eisai Books 18.7 Billion Yen in Payments to Medical Institutions in FY2013
September 2, 2014
- Astellas’ FY2013 Funding to Medical Institutions Totals 18.7 Billion Yen
September 2, 2014
- 33.2 Billion Yen Paid to Medical Institutions in FY2013: Daiichi Sankyo
September 2, 2014
- Takeda’s Payments to Health Professionals Down 30% in FY2013
September 2, 2014
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…